Target specific cross-linked heteroantibodies

Details Target specific cross-linked heteroantibodies Target specific cross-linked heteroantibodies

1985-09-23

1987-06-30

Kight, John

Drug, bio-affecting and body treating compositions

Lymphokine

424 88, 530387, G01N 3354, G01N 3358, G01N 3360

Patent

active

046769803

ABSTRACT:
The present invention discloses a target specific cross-linked heteroantibody and a method of producing the same. The cross-linked heteroantibodies of the present invention can cause normal autologous cells of the immune system to destroy any unwanted cell for which an antibody is available. Treatment or control of tumors, viral infected cells, fungi, bacteria, parasites and the like is now made possible through the use of the heteroantibody complex of the present invention.

REFERENCES:
patent: 4048298 (1977-09-01), Niswender
patent: 4433059 (1984-02-01), Chang et al.
patent: 4490473 (1984-12-01), Brunhouse
Staerz et al. (1985) Nature 314:628-631.
Kranz et al. (1984) Proc. Natl. Acad. Sci. Immun. 81:7922-7926.
Hoffman et al. (1985) Journ. of Immun. 135:1-4.
Lancki, et al. (1984) Immun. Reviews No. 80, 65-94.
Karpovsky et al. (1984) Journ. of Experim. Med. 160:1686-1701.

Affiliated with

Also associated with

Rating

Target specific cross-linked heteroantibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Target specific cross-linked heteroantibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Target specific cross-linked heteroantibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-447000